Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Autolus Therapeutics ( (AUTL) ) has provided an update.
Autolus Therapeutics reported fourth-quarter 2025 net product revenue of $23.3 million and full-year 2025 revenue of $74.3 million from AUCATZYL, driven by its first year of U.S. launch in adult relapsed or refractory B‑ALL, and confirmed that the product launched in the U.K. in January 2026 following a positive NICE evaluation. Real-world data from the ROCCA consortium covering about 60% of U.S. commercial patients showed safety and efficacy consistent with pivotal trial results, while the company raised cost of sales as it ramped commercial manufacturing, implemented a manufacturing lifecycle plan to lower costs and improve margins, and reiterated its 2026 revenue outlook alongside expectations of reaching positive gross margin and having liquidity to fund operations into the fourth quarter of 2027.
Across its pipeline, Autolus advanced obe‑cel into Phase 2 trials for pediatric relapsed or refractory B‑ALL and lupus nephritis after strong early remission and safety data, initiated the BOBCAT Phase 1 study in progressive multiple sclerosis in October 2025, and began dosing patients in the ALARIC Phase 1 trial of AUTO8 in light-chain amyloidosis, with multiple data readouts scheduled between late 2026 and 2028. This broad clinical program, including an RMAT designation for pediatric B‑ALL, positions the company to extend its CAR T platform into larger autoimmune and neurological markets, potentially diversifying revenue beyond AUCATZYL and reinforcing its competitive position in next-generation cell therapies.
The most recent analyst rating on (AUTL) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
The score is held back primarily by weak financial performance (large operating losses and substantial cash burn) and soft technicals (below major moving averages with negative MACD). Offsetting these, the latest earnings update reflects meaningful early commercialization progress and operational milestones, supporting a mid-range score despite valuation being difficult to assess due to negative earnings.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing, manufacturing and delivering next-generation programmed T cell therapies. Its lead product, the CAR T therapy AUCATZYL (obecabtagene autoleucel), targets relapsed or refractory B‑cell acute lymphoblastic leukemia and is being expanded into additional autoimmune and neurological indications.
Average Trading Volume: 1,941,695
Technical Sentiment Signal: Sell
Current Market Cap: $343.3M
See more data about AUTL stock on TipRanks’ Stock Analysis page.